Sharklet’s VP of Business Development, Dr. Ethan Mann, recently spoke about Sharklet at the TEDxMileHigh Conference. Check out the entire talk below:
Cardiovascular disease remains the leading cause of mortality among adults in the US. As a result, nearly 600,000 coronary and peripheral vascular bypass graft surgeries are performed in the US each year. To overcome limitations of current gold-standard auto-grafting and synthetic grafting methods, Sharklet Technologies, Inc. (STI) proposes a tissue engineered vascular graft comprised of a Sharklet micropatterned acellular extracellular matrix to enhance graft incorporation via guided endothelial cell migration onto the graft lumen.
Nearly 12 million wounds are treated in emergency departments throughout the United States every year. The limitations of current treatments for complex, full-thickness wounds are the driving force for the development of new wound treatment devices that result in faster healing of both dermal and epidermal tissue. Here, a bilayered, biodegradable hydrogel dressing that uses microarchitecture to guide two key steps in the proliferative phase of wound healing, re-epithelialization, and revascularization, was evaluated in vitro in a cell migration assay and in vivo in a bipedicle ischemic rat wound model.
During development of the ClearSight™ IOL, Sharklet researched the effect that micropatterned surfaces have on epithelial cells. After surgery to remove cataracts, an intraocular lens is inserted into the eye. Epithelial cells migrate onto the new lens, resulting in posterior capsule opacification (PCO). A followup surgery uses a laser to remove these migrated cells. The ClearSight IOL would feature a protective ring of Sharklet to prevent the cellular migration and negate the need for the laser procedure. Read More
Sharklet-patterned adhesive films are designed to be deployed in many environments, including hospitals. This study places Sharklet film in key areas of a simulated hospital room and measured transference between stations.
Environmental contamination contributes to an estimated 20-40% of all hospital acquired infections (HAI). Infection control practices continue to improve, but multipronged approaches are necessary to fully combat the diversity of nosocomial pathogens and emerging multidrug resistant organisms. The Sharklet™ micropattern, inspired from the microtopography of shark skin, was recently shown to significantly reduce surface contamination but has not been evaluated in a clinical setting. The focus of this study was the transfer of bacteria onto micropatterned surfaces compared to unpatterned surfaces in a clinical simulation environment involving healthcare practitioners.
Denver’s Channel 7 News, KMGH, ran a story and a short video interview with CEO Mark Spiecker.
Sharklet’s technology could keep dirty devices from making us sick, but it’s not just smartphone surfaces that could benefit.
“In hospitals right now, about 2 million a year get what are called hospital acquired infections. We spend about $30 billion a year treating those,” says Spiecker. “About 100,000 people die a year.”
Last year, Research Scientist Dr. Ethan Mann published a massive study on the performance of Sharklet against competitor anti-microbial technologies. Many outlets picked up on this study, including the Washington Post.
In experiments designed to mimic the transmission of bacteria via both touch and sneezes, the researchers found that Sharklet was more effective than copper, which is one of the most popular anti-microbial surfaces for hospital use. While copper harbored 80 percent less MRSA — antibiotic resistant bacteria — than control surfaces, Sharklet showed reductions of as much as 94 percent.